Biodesix announces research agreement with top us cancer center

Boulder, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (mrd) test as a part of a master sponsored research agreement (msra) with memorial sloan kettering cancer center (msk). in addition, the msra between msk and biodesix also includes the potential future development of other diagnostic tests aimed at improving the treatment o
BDSX Ratings Summary
BDSX Quant Ranking